Brean Capital Reiterates Buy on Alexion Pharma (ALXN) Following Exteneded Priority Review Date
Tweet Send to a Friend
Brean Capital reiterated a Buy rating and $221.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's announcement that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
